News
ASRT
4.010
-2.67%
-0.110
Assertio Holdings Scores With New Broadly-Covered Asset
Seeking Alpha · 01/20 22:43
Assertio Holdings: This Top-Rated Stock Is Still Undervalued
Seeking Alpha · 01/19 12:38
BRIEF-Assertio Announces Partnership With Lennox-Gastaut Syndrome Foundation
Reuters · 01/17 14:20
Assertio Announces Partnership With The Lennox-Gastaut Syndrome Foundation
Benzinga · 01/17 14:02
BRIEF-Assertio Holdings Inc Announces FDA Orange Book Listing For New Sympazan Oral Film Patent
Reuters · 01/09 22:05
Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco
Meetings to Take Place Adjacent to JP Morgan Healthcare ConferenceLAKE FOREST, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products...
GlobeNewswire · 12/13/2022 19:07
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12/06/2022 17:24
BRIEF-Assertio Increases Full-Year Net Product Sales Outlook To In Excess Of $152 Mln
Reuters · 12/05/2022 12:43
Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million
LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it is raising its outlook for 2...
GlobeNewswire · 12/05/2022 12:30
TKC, AIU and NRBO are among pre market gainers
Seekingalpha · 11/09/2022 13:33
BRIEF-Assertio Reports Third Quarter 2022 Financial Results
Reuters · 11/08/2022 23:05
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08/2022 22:45
UPDATE: Assertio Therapeutics Q3 Adj. EPS $0.22 Beats $0.07 Estimate
Benzinga · 11/08/2022 22:05
Assertio Therapeutics Non-GAAP EPS of $0.22 beats by $0.11, revenue of $34.21M beats by $2.86M
Seekingalpha · 11/08/2022 21:26
Assertio Raises FY22 GAAP Sales From $129M-$137M To $141M+; Adjusted Non-GAAP EBITDA From $73M-$79M To $86M+
Benzinga · 11/08/2022 21:06
Assertio Therapeutics Q3 EPS $0.08 Beats $0.07 Estimate, Sales $34.21M Beat $31.33M Estimate
Benzinga · 11/08/2022 21:02
-- Earnings Flash (ASRT) ASSERTIO HOLDINGS Posts Q3 EPS $0.22, vs. Street Est of $0.11
-- Earnings Flash (ASRT) ASSERTIO HOLDINGS Posts Q3 EPS $0.22, vs. Street Est of $0.11
MT Newswires · 11/08/2022 16:23
Lake Street Initiates Coverage On Assertio Holdings with Buy Rating, Announces Price Target of $7
Benzinga · 11/07/2022 15:02
--Lake Street Initiates Assertio Therapeutics at Buy Rating With $7 Price Target
--Lake Street Initiates Assertio Therapeutics at Buy Rating With $7 Price Target
MT Newswires · 11/07/2022 11:51
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2...
GlobeNewswire · 10/27/2022 20:05
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
Assertio Holdings, Inc. is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. The Company's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The Company has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.